Gilead Stops Magrolimab Development
Magrolimab for myelodysplastic syndromes is discontinued by Gilead
SG Tylor
Source – Gilead Science Gilead Sciences has announced the discontinuation of its cancer antibody, magrolimab, in the treatment of blood ...
